FindTrial
Sign In

Clinical study of 18F-AMG510 PET/CT imaging in the accurate diagnosis of tumor KRAS mutations

Clinical study of 18F-AMG510 PET/CT imaging in the accurate diagnosis of tumor KRAS mutations

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300070135
Enrollment
Unknown
Registered
2023-04-03
Start date
2022-07-04
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tumor

Interventions

Gold Standard:KRAS Gene Test
Index test:18F-AMG510 PET/CT

Sponsors

Xijing hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients with pathologically confirmed and genetically tested KRAS mutations in their tumors.

Exclusion criteria

Exclusion criteria: Those who without verification of pathological results, minors, pregnant and lactating women, and those with severe hepatic and renal insufficiency (Alanine aminotransferase exceeded the upper limit of normal by a factor of 8-10, and serum creatinine was 186-442 µmol/L).

Design outcomes

Primary

MeasureTime frame
Tumor SUVmax;Tumor size;No. of lesions;—

Secondary

MeasureTime frame
Normal organs SUVmax;—

Countries

China

Contacts

Public ContactWang Jing

Xijing hospital

13909245902@163.com029-84771048

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026